LabCorp Extends Bid for Orchid Cellmark for Seventh Time | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Laboratory Corporation of America today announced it has extended its $85.4 million bid for Orchid Cellmark to 5 p.m. EDT Nov. 4.

It is the seventh time the proposed deal, in which LabCorp will pay $2.80 for each share of Orchid stock, has been extended. It previously had been extended to Oct. 7.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.